In March 2023 the Company received feedback from the FDA pertaining to its clinical development plans and intent to proceed with a mul-site Phase 2 study in the U.S. The Phase 2 study will be used to opmize dose and imaging schedules as well as explore various endpoints for clinical validity.
- Forums
- ASX - By Stock
- IBX
- Ann: Imagion to complete the MagSense HER2 Phase 1 Study
Ann: Imagion to complete the MagSense HER2 Phase 1 Study, page-4
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IBX (ASX) to my watchlist
|
|||||
Last
5.3¢ |
Change
-0.008(13.1%) |
Mkt cap ! $2.099M |
Open | High | Low | Value | Volume |
6.0¢ | 6.0¢ | 5.3¢ | $5.718K | 99.96K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 115001 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 1102 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 115001 | 0.052 |
1 | 19999 | 0.050 |
1 | 59181 | 0.049 |
1 | 16300 | 0.045 |
1 | 13000 | 0.040 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 1102 | 1 |
0.055 | 261 | 1 |
0.058 | 14821 | 1 |
0.061 | 1170 | 1 |
0.062 | 3988 | 3 |
Last trade - 12.21pm 23/07/2024 (20 minute delay) ? |
Featured News
IBX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online